Research programme: oxytocin intranasal - Pastorus Pharma

Drug Profile

Research programme: oxytocin intranasal - Pastorus Pharma

Latest Information Update: 15 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shin Nippon Biomedical Laboratories
  • Developer Pastorus Pharma; Shin Nippon Biomedical Laboratories
  • Class Hormones; Oxytocics
  • Mechanism of Action Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Autistic disorder

Most Recent Events

  • 15 Oct 2013 No development reported for Autistic disorder in USA (Intranasal)
  • 10 Feb 2011 Early research in Autistic disorder in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top